Çağatay Arslan - Concepedia

Author

Çağatay Arslan

Also Known As

Arslan Cagatay, C Arslan, C. Arslan, CAGATAY ARSLAN, Cagatay ARSLAN, Cagatay Arslan, Cağatay Arslan, Ceren ARSLAN, Ceyda Arslan, Hakkı Caner İnan

214

Publications

Citations

H-Index

Concepts

All Affiliations

Hacettepe University Hacettepe University Hospital Izmir University Merck & Co., Inc., Rahway, NJ, USA (United States)Süleyman Demirel University

ÇA

About

Çağatay Arslan is an author at Hacettepe University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	4.4K
2	Health Sciences	2	2	1.8K
3	Cell Biology	2	2	26
4	Public Health	1	1	26
5	Biochemistry	1	1	27

Çağatay Arslan

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Javier Cortés, David W. Cescon, Hope S. Rugo, The Lancet Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer	2020	1.7K
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, NEJM Evidence UrologyGenitourinary CancerMedicineOlaparib ArmPolymerase Inhibitor Olaparib	2022	357
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, The Lancet Oncology Concurrent ChemoradiotherapyNeoadjuvant TherapySquamous Cell CarcinomaMedicineHead And Neck Cancer	2024	174
The effect of long-term low-dose lead exposure on thyroid function in adolescents Bumin Nuri Dündar, Faruk Öktem, Meltem Koyuncu Arslan, Environmental Research Thyroid FunctionThyroid DiseaseThyroid DisordersToxicologyThyroid Hormone	2006	83
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Fred Saad, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Journal of Clinical Oncology Androgen ReceptorEndocrine OncologyUrologyOncologyGenitourinary Cancer	2022	80
Osteosclerosis due to endemic fluorosis Mehmet Numan Tamer, Banu Kale Köroğlu, Çağatay Arslan, The Science of The Total Environment Bone DiseaseRheumatologyEndemic FluorosisOsteopathyOsteoarthritis	2006	75
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study Alwin Krämer, Tilmann Bochtler, Chantal Pauli, The Lancet Therapy Versus ChemotherapyHealth SciencesMedicineUnknown PrimaryPathology	2024	58
Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome): a report of two cases and review of the literature Şevket Ercan Tunç, Çağatay Arslan, Naime Bayram Ayvacioglu, Rheumatology International RheumatologyPathologyRs3pe SyndromeSeronegative Symmetrical SynovitisDermatology	2003	41

Page 1